-
Recro Pharma Announces Pricing of Public Offering of Common Stock
-
Roth Capital Starts Recro Pharma (REPH) at Buy
-
Notable Analyst Rating Changes 8/29: (CBL) (ATI) (KS) Upgraded; (HAYN) (KEY) (SQ) Downgraded
-
Unusual 11 Mid-Day Movers 3/10: (CASI) (REPH) (JOB) Higher; (NNBR) (IDT) (TITN) Lower

